Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155593 · ClinicalTrials.gov registry record
In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder
A clinical trial, sponsored by TriHealth.
- Completed
- Registry status
- 135
- Enrollment target
NCT04155593: Completed study, sponsored by TriHealth.
NCT04155593 is a clinical trial that has completed, run by TriHealth. The registered enrollment target is 135 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155593 has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the rates of elevated post void residual (PVR) (defined as \>200mL) in Cincinnati Urogynecology Associates patients following Botox injection, as well as to document how many patients required treatment with clean intermittent self-catheterization (CISC).
Primary Outcome
Number of subjects with PVR \> 200mL following Botox injection for OAB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2020-07-15 |
What the finished NCT04155593 record still lists
NCT04155593 is an observational study that tracks outcomes without assigning an intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04155593 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04155593 about?
NCT04155593 is a clinical study titled "In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder". The purpose of this study is to describe the rates of elevated post void residual (PVR) (defined as \>200mL) in Cincinnati Urogynecology Associates patients following Botox injection, as well as to document how many patients required treatment with clean intermittent self-catheterization (CISC).
What is the current status of trial NCT04155593?
This trial is currently completed. The enrollment target is 135 participants. The study started on 2019-11-08. Estimated completion is 2020-07-15.
Who is sponsoring clinical trial NCT04155593?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI